Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M35,714Revenue $M7,720Net Margin (%)11.1Altman Z-Score2.5
Enterprise Value $M43,987EPS $2.3Operating Margin %16.2Piotroski F-Score6
P/E(ttm)33.1Beneish M-Score-2.2Pre-tax Margin (%)11.2Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %12.4Quick Ratio1.0Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %8.3Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow110y-y EBITDA Growth Rate %10.3ROA % (ttm)5.2Higher Current Ratio y-yN
Dividend Yield %--PEG3.9ROE % (ttm)19.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M490ROIC % (ttm)9.8Gross Margin Increase y-yY

Gurus Latest Trades with MYL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYLJoel Greenblatt 2015-03-31 Reduce-0.3%$52.74 - $64.96
($57.01)
$ 72.0426%Reduce 97.62%16,021
MYLVanguard Health Care Fund 2015-03-31 Add0.11%$52.74 - $64.96
($57.01)
$ 72.0426%Add 5.68%15,891,898
MYLFirst Eagle Investment 2015-03-31 Reduce-0.04%$52.74 - $64.96
($57.01)
$ 72.0426%Reduce 30.38%586,016
MYLJohn Paulson 2014-12-31 Add0.72%$46.5 - $58.62
($53.92)
$ 72.0434%Add 19.64%14,948,400
MYLJoel Greenblatt 2014-12-31 Buy 0.31%$46.5 - $58.62
($53.92)
$ 72.0434%New holding673,287
MYLVanguard Health Care Fund 2014-12-31 Reduce-0.05%$46.5 - $58.62
($53.83)
$ 72.0434%Reduce 2.64%15,037,080
MYLFirst Eagle Investment 2014-12-31 Add$46.5 - $58.62
($53.83)
$ 72.0434%Add 3.97%841,779
MYLVanguard Health Care Fund 2014-09-30 Add1.24%$44.97 - $52.34
($48.56)
$ 72.0448%Add 223.41%15,444,880
MYLFirst Eagle Investment 2014-09-30 Reduce-0.06%$44.97 - $52.34
($48.56)
$ 72.0448%Reduce 34.81%809,603
MYLMario Gabelli 2014-09-30 Reduce$44.97 - $52.34
($48.56)
$ 72.0448%Reduce 27.54%10,000
MYLFirst Eagle Investment 2014-06-30 Add0.07%$45.72 - $52.1
($49.11)
$ 72.0447%Add 83.88%1,241,991
MYLFirst Eagle Investment 2014-03-31 Buy 0.09%$42.26 - $57.2
($48.38)
$ 72.0449%New holding675,428
MYLJoel Greenblatt 2014-03-31 Sold Out -0.01%$42.26 - $57.2
($48.38)
$ 72.0449%Sold Out0
MYLDavid Dreman 2014-03-31 Sold Out $42.26 - $57.2
($48.38)
$ 72.0449%Sold Out0
MYLJoel Greenblatt 2013-12-31 Reduce$37.865 - $44.5
($41.09)
$ 72.0475%Reduce 31.83%7,291
MYLDavid Dreman 2013-12-31 Buy $37.865 - $44.5
($41.09)
$ 72.0475%New holding1,221
MYLJoel Greenblatt 2013-09-30 Reduce-0.16%$30.37 - $38.95
($35.23)
$ 72.04104%Reduce 91.73%10,695
MYLJohn Paulson 2013-06-30 Reduce-0.98%$27.96 - $31.87
($29.87)
$ 72.04141%Reduce 32.83%12,139,300
MYLJoel Greenblatt 2013-06-30 Add0.15%$27.96 - $31.87
($29.87)
$ 72.04141%Add 668.47%129,295
MYLVanguard Health Care Fund 2013-06-30 Add0.07%$27.96 - $31.87
($29.87)
$ 72.04141%Add 14.36%4,775,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MYL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cindrich Robert JDirector 2015-02-03Sell40,645$53.1537.12view
CAMERON WENDYDirector 2015-02-03Sell106,551$53.1537.12view
COURY ROBERT JExecutive Chairman 2015-02-03Sell947,119$52.5538.69view
Malik RajivPresident 2015-02-03Sell285,394$53.1537.12view
MAROON JOSEPH C MDDirector 2015-02-03Sell136,551$53.1537.12view
BRESCH HEATHER MCEO 2015-02-03Sell411,996$53.1537.12view
DIMICK NEIL FDirector 2015-02-03Sell19,781$53.1537.12view
Mauro AnthonyPresident, North America 2015-02-03Sell13,255$53.1537.12view
LEECH DOUGLAS JDirector 2015-02-03Sell62,271$53.1537.12view
VANDERVEEN RANDALL LDirector 2015-02-03Sell106,551$53.1537.12view

Press Releases about MYL :

    Quarterly/Annual Reports about MYL:

      News about MYL:

      Articles On GuruFocus.com
      Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
      Tom Russo Buys 3 New Stocks in Q1 May 18 2015 
      Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
      Teva Eyeing Mylan For $40 Billion Apr 23 2015 
      CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
      Vanguard Health Care Fund Comments on Mylan NV Mar 27 2015 
      Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
      Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
      Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 
      John Paulson's Top Buys Feb 21 2015 

      More From Other Websites
      With A $1.2 Billion Hammer, The FTC Closes Loophole To Prevent Generic Drugs May 28 2015
      Teva Buying Mylan Stock May Portend Showdown at Investor Meeting May 28 2015
      Teva increases pressure on $40bn takeover target Mylan May 27 2015
      After-hours buzz: Palo Alto, Teva, Analog & more May 27 2015
      Mylan to Present at the Bernstein Strategic Decisions Conference May 26 2015
      Exclusive: Mylan chairman says Teva offers nothing we can't do on our own May 26 2015
      Five things to know today, and why Mylan NV didn't take a holiday May 26 2015
      2:07 am Mylan Labs issues clarification Irish Takeover Panel relating to its intention to acquire... May 26 2015
      Mylan/Perrigo Clarification May 25 2015
      Dealpolitik: Why Lawyers Need to Care About the Mylan-Kirkland Battle May 22 2015
      How Much is Actavis Worth? A Lot More Than It is Now May 22 2015
      Law Firm Advising Teva Dismisses Mylan Objections May 21 2015
      Theravance Biopharma Presents Additional Positive Phase 2b Study Data on TD-4208 May 20 2015
      Five things to know today, and a big golden parachute in Heinz merger May 19 2015
      Endo Buying Par Pharma To Become Top Generics Player May 18 2015
      Endo pushes further into generics with $8 billion Par Pharma buy May 18 2015
      Endo pushes further into generics with $8 bln Par Pharma buy May 18 2015
      Perrigo CEO Says Ready to Talk Deal With Mylan at Right Price May 18 2015
      Growing 29% YTD, Cross-Border M&As Near $594 Billion May 14 2015
      Dealpolitik: 2015 May Be an Expensive Tax Year for Some Mylan Shareholders May 13 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK